In a multicenter Phase I trial with a Phase Ib expansion, MRG003 was administered at a recommended dose of 2.5 mg/kg every three weeks in patients with refractory, EGFR-positive advanced HNSCC [114]. This evidence concerns the gene EGFR and head and neck squamous cell carcinoma.